All News

2018

January

Media Release / Jan 22, 2018

AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read More
Media Release / Jan 16, 2018

AveXis Announces Pricing of Public Offering of Common Stock

Read More
Media Release / Jan 16, 2018

AveXis Announces Proposed Public Offering of Common Stock

Read More
Media Release / Jan 16, 2018

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

Read More
Media Release / Jan 08, 2018

REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

Read More
Media Release / Jan 04, 2018

AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More